512 related articles for article (PubMed ID: 28346110)
21. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy.
Veerapandiyan A; Pal R; D'Ambrosio S; Young I; Eichinger K; Collins E; Westesson PL; Kwon J; Ciafaloni E
Neurology; 2018 Aug; 91(7):e620-e624. PubMed ID: 30006410
[TBL] [Abstract][Full Text] [Related]
22. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
[TBL] [Abstract][Full Text] [Related]
23. Nusinersen (Spinraza) for spinal muscular atrophy.
Med Lett Drugs Ther; 2017 Mar; 59(1517):50-52. PubMed ID: 28323809
[No Abstract] [Full Text] [Related]
24. Risdiplam: First Approval.
Dhillon S
Drugs; 2020 Nov; 80(17):1853-1858. PubMed ID: 33044711
[TBL] [Abstract][Full Text] [Related]
25. Nusinersen in type 0 spinal muscular atrophy: should we treat?
Tiberi E; Costa S; Pane M; Priolo F; de Sanctis R; Romeo D; Tiziano FD; Conti G; Vento G; Mercuri E
Ann Clin Transl Neurol; 2020 Dec; 7(12):2481-2483. PubMed ID: 33147378
[TBL] [Abstract][Full Text] [Related]
26. Antisense oligonucleotides and spinal muscular atrophy: skipping along.
Burghes AH; McGovern VL
Genes Dev; 2010 Aug; 24(15):1574-9. PubMed ID: 20679391
[TBL] [Abstract][Full Text] [Related]
27. FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga.
Aartsma-Rus A; Krieg AM
Nucleic Acid Ther; 2017 Feb; 27(1):1-3. PubMed ID: 27929755
[No Abstract] [Full Text] [Related]
28. New Therapy for Spinal Muscular Atrophy Offers Modest Bang for Pharamaceutical Buck.
Morrow T
Manag Care; 2017 Feb; 26(2):36-37. PubMed ID: 28271991
[TBL] [Abstract][Full Text] [Related]
29. Sense in antisense therapy for spinal muscular atrophy.
MacKenzie A
N Engl J Med; 2012 Feb; 366(8):761-3. PubMed ID: 22356331
[No Abstract] [Full Text] [Related]
30. FDA-Approved Oligonucleotide Therapies in 2017.
Stein CA; Castanotto D
Mol Ther; 2017 May; 25(5):1069-1075. PubMed ID: 28366767
[TBL] [Abstract][Full Text] [Related]
31. Antisense-based therapy for the treatment of spinal muscular atrophy.
Rigo F; Hua Y; Krainer AR; Bennett CF
J Cell Biol; 2012 Oct; 199(1):21-5. PubMed ID: 23027901
[TBL] [Abstract][Full Text] [Related]
32. The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy.
Aartsma-Rus A; Corey DR
Nucleic Acid Ther; 2020 Apr; 30(2):67-70. PubMed ID: 32043902
[No Abstract] [Full Text] [Related]
33. Romancing the spliceosome to fight spinal muscular atrophy.
Swoboda KJ
N Engl J Med; 2014 Oct; 371(18):1752-4. PubMed ID: 25354110
[No Abstract] [Full Text] [Related]
34. Antisense Oligonucleotides: A Unique Treatment Approach.
Krishnan AV; Mishra D
Indian Pediatr; 2020 Feb; 57(2):165-171. PubMed ID: 32060244
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.
Singh NN; Lee BM; DiDonato CJ; Singh RN
Future Med Chem; 2015; 7(13):1793-808. PubMed ID: 26381381
[TBL] [Abstract][Full Text] [Related]
37. Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review.
Meylemans A; De Bleecker J
Acta Neurol Belg; 2019 Dec; 119(4):523-533. PubMed ID: 31388901
[TBL] [Abstract][Full Text] [Related]
38. Advances in therapy for spinal muscular atrophy: promises and challenges.
Groen EJN; Talbot K; Gillingwater TH
Nat Rev Neurol; 2018 Apr; 14(4):214-224. PubMed ID: 29422644
[TBL] [Abstract][Full Text] [Related]
39. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
[TBL] [Abstract][Full Text] [Related]
40. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.
d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ
Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
